We are live on ! Find out more
AVEO

AVEO Pharmaceuticals

Delisted

AVEO was delisted on the 19th of January, 2023.

49 hedge funds and large institutions have $22.5M invested in AVEO Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 6

54% more capital inflows, than outflows

Capital inflows: $2.68M | Capital outflows: $1.74M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.36% less ownership

Funds ownership: 28.73% → 28.37% (-0.36%)

4% less funds holding

Funds holding: 51 → 49 (-2)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $116K

Holders
49
Holders Change
-2
Holders Change %
-3.92%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
17
Reduced
6
Closed
11
Calls
–
Puts
$116K
Net Calls
-$116K
Net Calls Change
-$38K

AVEO Hedge Fund Activity: Q1 2015 in Review

49 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q1 2015, worth a combined $22.5M — up 78% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of AVEO and 9 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 17 added.

The largest buyer was Renaissance Technologies, adding an estimated $656K. The largest seller was D.E. Shaw & Co, cutting an estimated $886K.

  • 49 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q1 2015, down from 51 in Q4 2014.
  • Funds reported $22.5M of AVEO Pharmaceuticals stock for Q1 2015, up 78% quarter-over-quarter.
  • 9 funds opened new AVEO Pharmaceuticals positions in Q1 2015 and 11 closed out, a net change of -2 holders.
  • The largest AVEO Pharmaceuticals buyer in Q1 2015 was Renaissance Technologies, an estimated $656K added.
  • The largest AVEO Pharmaceuticals seller in Q1 2015 was D.E. Shaw & Co, an estimated $886K sold.

Based on aggregated 13F filings for Q1 2015.